Abstract: A plurality of sensing devices are inserted into a concrete mixture to be used at a construction site. The concrete mixture is poured to form one or more structural elements, wherein one or more sensing devices are embedded in the concrete of each structural element. Data relating to a first characteristic of the concrete in each structural element is received from the sensing devices. For each structural element, a second characteristic of the concrete of the associated structural element is determined, based on the first characteristic. A map showing the one or more structural elements is generated. For each of the one or more structural elements, a respective graphical indicator indicating the second characteristic associated with the respective structural element is displayed on the map. The map is displayed on a user device.

Abstract: Compositions including reclaimed asphalt may be optimized for performance that is comparable with asphalt compositions that do not contain any reclaimed asphalt. In a method to determine an optimal level of reclaimed asphalt for use with at least a rejuvenator, TSRST tests are carried out on test asphalt compositions with varying levels of reclaimed asphalt (RA) materials to obtain failure temperature and failure stress data for all compositions. The test results are compared to identify composition(s) with optimal amount of RA. The optimal asphalt composition containing the maximum amount of RA for comparable performance may have a failure temperature within±5% of the failure temperature of the reference composition, and a failure stress that may be equal to or greater than the failure stress of the reference composition.

Abstract: There is described a process for improving precision in an analytical test for a target analyte in a sample. The process includes prior to analyzing the sample for a target analyte via a biosensor, introducing to an analytical zone defined by the biosensor fluid comprising an effective amount of the target analyte.

Abstract: An image processing apparatus contains an input unit to input a fluorescent image and a morphological image of a tissue. A biological substance expressed at a first structure of a cell in the tissue is stained by a fluorescent substance. The fluorescent image illustrates a fluorescent bright point which represents expression of the biological substance. The morphological image illustrates a morphology of a second structure of a cell in the tissue and contains the same range of the tissue as the fluorescent image. The apparatus further contains a feature amount extraction unit to extract a feature amount of the second structure from the morphological image, a bright point extraction unit to extract the fluorescent bright point from the fluorescent image, and a region of interest determination unit to determine a region of interest based on the feature amount of the second structure and a distribution of the fluorescent bright point.

Abstract: An alternating signal is applied across a nanopore of a sequencing cell, the nanopore being configured to receive a tag that is connected to a nucleotide, thereby creating a threading event. A first set of voltage data is acquired during a first portion of a plurality of cycles of the alternating signal. Each data point of the first set of voltage data corresponds to a value of a resistance of the nanopore at a different time, where the resistance of the nanopore changes when the tag is received within the nanopore. A shifted set of voltage data is determined from the first set of voltage data and difference data is computed by computing differences between data points of the first set of voltage data and corresponding data points of the shifted set of voltage data. Threading events may be identified based on the difference data.

Abstract: Improved multi-cell nanopore-based sequencing chips and methods can employ formation, characterization, calibration, and/or normalization techniques. For example, various methods may include one or more steps of performing physical checks of cell circuitry, forming and characterizing a lipid layer on the cells, performing a zero point calibration of the cells, forming and characterizing nanopores on the lipid layers of each cell, performing a sequencing operation to accumulate sequencing signals from the cells, normalizing those sequencing signals, and determining bases based on the normalized sequencing signals.

Abstract: This disclosure relates to the detection of whole blood hemolysis in a sample of whole blood. More specifically, this disclosure describes detecting hemolysis using one or more novel ratios of intercellular concentrations of whole blood analytes.

Abstract: This determination method comprises the steps consisting of providing a reaction vessel (2) containing a blood sample (33) and a ferromagnetic ball (11) placed on a raceway (9) provided in the bottom of the reaction vessel (2), subjecting the ball (11) to a magnetic field so as to move the ball along the raceway (9) in an oscillatory motion, exposing the blood sample to an incident light beam (36), detecting a light beam (38) transmitted through the reaction vessel (2) and coming from the incident light beam (36) in such a way as to provide a measurement signal, carrying out a first processing of the measurement signal in such a way as to provide a first signal representative of the variation of at least one physical quantity representative of the movement of the ball (11), carrying out a second processing of the measurement signal in such a way as to provide a second signal representative of the variation of at least one optical property of the blood sample, determining a first value of the coagulation time

Abstract: Methods to rapidly and accurately detect, characterize, measure, and quantify site-specific antibody drug conjugates, that may be present in pre-clinical animal biological samples, or human biological samples, including plasma/serum and tissue samples.

Abstract: A method of identifying a potential therapeutic compound that affects a Receptor Tyrosine Kinase (RTK) pathway in cancer cells, which includes: providing a device capable of measuring cell-substrate impedance; culturing cancer cells in serum-free media in at least two wells of the device; adding to a first well a proposed therapeutic compound that affects a RTK pathway and a RTK stimulating factor for the RTK pathway to form a test well, and adding to another well the RTK stimulating factor to form a control well; continuously monitoring cell-substrate impedance of the at least two wells and optionally determining cell indices from the monitored cell-substrate impedance; and determining a difference in impedance or optionally cell index between the test well and control well; and if significantly different, concluding the proposed therapeutic compound is therapeutically active in the RTK pathway within the cancer cells.

Abstract: Exemplary embodiments provide in vitro brain models, such as in vitro models of a neurovascular unit or a functionally connected trineural pathway, and systems, devices and methods of use thereof. The present invention provides in vitro brain models, systems, devices and methods that mimic in vivo conditions to, for example, determine the effect of a test compound, such as a drug candidate or a toxin, on various biological responses, such as for example, cell viability, cell growth, migration, differentiation and maintenance of cell phenotype, metabolic activity, structural remodeling and tissue level pre-stress, a neural activity, such as an electrophysiological activity.

Abstract: The present invention relates to a system and methods for identifying a compound for de-fatting and functional recovery of macrosteatotic hepatocytes.

Abstract: The present invention relates to a method for determining the distinctive nutritional requirements of a patient with specific nutritional needs and providing a composition meeting the distinctive nutritional requirements of said patient.

Abstract: The present invention relates to a method for the diagnosis of a disease comprising contacting a donor tissue section with a liquid capable of extracting an antibody from said donor tissue section and contacting said liquid with an acceptor material comprising an antigen, followed by detection of a complex comprising the antibody and the antigen, and a diagnostically useful carrier comprising a donor tissue section and an acceptor material comprising an antigen.

Abstract: A system and method for quantifying white blood cells in a blood sample is described. The system includes a sample medium for depositing the same blood. The sample medium is positioned between a first electrode and a second electrode. The system also includes an electrical analyser for supping pulsing sweeping voltage across the electrodes through the sample medium. The electrical analyser is also configured for measuring capacitance across the sample medium before and after adding a chemical analyte. The system also includes a general processor in electrical or wireless communication with the electrical analyser configured for quantifying the white blood cells in the blood sample based on the generated capacitance-voltage profile. The method is described to operate the system and to quantify the white blood cells in a blood sample.

Abstract: Herein is reported a method for the detection of a sortase in a sample, comprising the following steps: a) incubating the sample with a first substrate comprising an immobilization tag and a second substrate comprising a detectable label, whereby in the presence of a sortase in the sample a conjugate comprising the immobilization tag and the detectable label is formed, b) immobilizing the conjugate of step a) via/using the immobilization tag to a solid phase, c) detecting the immobilized conjugate via/using the detectable label and thereby detecting the sortase in the sample.

Abstract: The present invention provides self-contained systems, apparatus and methods for determining a chemical state, the system includes a stationary cartridge for performing the assay therein, the cartridge adapted to house at least one reagent adapted to react with a sample; and at least one reporter functionality adapted to report a reaction of the at least one reagent with the sample to report a result of the assay, a mechanical controller including a first urging means adapted to apply a force externally onto the cartridge to release the at least one reagent; and at least one second urging means adapted to apply a removable force to induce fluidic movement in a first direction in the cartridge and upon removal of the force causing fluidic movement in an opposite direction to the first direction, an optical reader adapted to detect the reaction and a processor adapted to receive data from the optical reader and to process the data to determine said chemical state.

Abstract: The invention relates to a process for preparation of an unpassivated cantilever comprising the steps of: 1) providing a silicon cantilever sensor having two sides; 2) coating one side of the cantilever with at least a gold layer; and 3) functionalizing both sides of the cantilever with a self-assembled monolayer (SAM) of a probe molecule by incubating the cantilever in a solution having a concentration of the probe molecule of between 1 to 1000 ?M. The invention also relates to an unpassivated cantilever sensor comprising a silicon layer coated on one side with a coating comprising Au and being uncoated or unpassivated on the opposite side, wherein the Au coated surface comprises a self-assembled monolayer of a probe molecule and wherein the surface area occupied per probe molecule is in the range 0.4-1.5 nm2.

Abstract: The disclosure provides method and composition utilizing fluorescent amino acids and fluorescent proteins comprising a moiety capable of undergoing FRET. The methods and compositions of the disclosure are useful in analyzing protein structure and function, and screening molecular inhibitors.

Abstract: The invention relates to a sensor molecule for detecting a target molecule comprising: (a) a rod-like molecule L and a rod-like molecule R connected to each other by a joint molecule C to form a hinge; (b) a target binding molecule A bonded to the end of rod-like molecule L opposite to the joint molecule C; (c) a binding molecule A? bonded to the end of rod-like molecule R opposite the joint molecule C; wherein the target binding molecule A is arranged to bind to the target molecule to be detected, and binding molecule A? is arranged to bind to: i) the same target molecule as target binding molecule A; or ii) a complex of the target binding molecule A and the target; and wherein the hinge is biased into an open position, such that target binding molecule A and binding molecule A? are biased apart by the hinge.

Abstract: A device for identifying the presence of a specific target molecule or biomarker by the detection of a change in an electrical property includes a measurement sensor 8 comprising a semiconducting sensor structure 12 capable of conjugating with the biomarker, thus giving rise to the said change in electrical property, and an electrode system 3, 4 for conducting a signal from the device. According to the invention there is a further such sensor 9, of substantially identical form but having its sensor structure 14 already conjugated with the biomarker, or otherwise capped, e.g. using a further oligonucleotide strand, so as to act as an internal reference. When a biological sample, e.g. saliva, is applied to the electrodes, the reference enables the discounting of all environmental effects other than the biomarker. The invention provides a simple, cheap and accurate test for one or more biomarkers that can be used in the field without complex equipment.

Abstract: Kits and methods according to aspects of the present invention relate to the detection and quantitation of small molecule analytes including 8-hydroxyguanosine, 8-hydroxyguanine, and 8-hydroxy-2?-deoxyguanosine.

Abstract: The present invention relates to a method for detecting an analyte in a sample, comprising the steps of: forming on each of carrier particles a complex containing a first capture substance capable of binding to an analyte, one molecule of the analyte, a second capture substance capable of binding to the analyte, and a catalyst; immobilizing a reaction product on each of the carrier particles by reacting the catalyst in the compolex with a substrate; and detecting the analyte by detecting the carrier particles on each of which the reaction product is immobilized.

Abstract: The present invention provides a method and microfluidic immunoassay pScreen™ device for detecting and quantifying the concentration of an analyte in a liquid sample by using antigen-specific antibody-coated magnetic-responsive micro-beads. The methods and devices of the present invention have broad applications for point-of-care diagnostics by allowing quantification of a large variety of analytes, such as proteins, protein fragments, antigens, antibodies, antibody fragments, peptides, RNA, RNA fragments, functionalized magnetic micro-beads specific to CD4+, CD8+ cells, malaria-infected red blood cells, cancer cells, cancer biomarkers such as prostate specific antigen and other cancer biomarkers, viruses, bacteria, and other pathogenic agents, with the sensitivity, specificity and accuracy of bench-top laboratory-based assays.

Abstract: A fluidic device includes: a circulation flow path; and a capture part arranged on the circulation flow path and configured to capture a sample substance in a solution and/or a detection part arranged on the circulation flow path and configured to detect a sample substance in a solution.

Abstract: A plasmonic device is disclosed, the plasmonic device having a base substrate and an electrically conductive film formed on the base substrate. The base substrate has a reference upper surface and an arrangement of chiral nanostructures formed in relief from the reference upper surface. Each chiral nanostructure has a nanostructure upper surface which is disposed at a distance of at least 30 nm from the reference upper surface in a thickness direction. The electrically conductive film is formed on the nanostructure upper surface of each chiral nanostructure and on at least part of the reference upper surface of the base substrate. Also disclosed is a method of analysis of a biological material using the plasmonic device, by depositing the biological material onto the plasmonic device and irradiating the plasmonic device and the biological material with electromagnetic radiation.

Abstract: [Problem] To provide a target substance detection chip, a target substance detection device, and a target substance detection method, that can be manufactured easily in a small size at low costs with reduction of the number of parts involved in the detection chip constituted by an optical prism and a detection plate used for a SPR sensor and an optical waveguide mode sensor, that can detect a target substance quickly with high sensitivity, and in which an analyte liquid is easily delivered.

Abstract: Lateral flow methods and apparatuses for detecting one or more analytes are provided. Certain embodiments provide a lateral flow device, kit and method of using the same, comprising: a flow path defined by a permeable sub-assembly of the lateral flow device, a release zone comprising a plurality of peptide-tagged agents, and a detection zone comprising a plurality of anti-peptide agents present in the flow path at a ratio of at least 100:1, on a weight:weight basis, relative to the plurality of peptide-tagged agents.

Abstract: A problem of the present invention is to provide an immunochromatographic test strip avoiding agglutination of colloidal gold while red blood cells in whole blood are agglutinated and then separated and removed in the case of using polybrene as a hemagglutinating agent and the colloidal gold conjugates as a detection reagent, and to provide immunochromatography using the test strip. To solve the problem, the present inventors reviewed the composition of the existing reagent itself from a completely different viewpoint rather than the selection of type or amount of polyanions, and as a result of extensive study on each element, the inventors surprisingly found that agglutination of colloidal gold may be suppressed by using a particular additive without neutralization by polyanions.

Abstract: The invention provides a method of measuring the affinity of first and second biomolecules in which a first biomolecule is tethered by a first tether portion having a first tether portion length and a second biomolecule is tethered by a second tether portion having a second tether portion length, the method comprising determining binding of adjacent first and second biomolecules to each other, varying at least one of the first and second tether lengths and determining binding of the first and second biomolecules. The invention also provides apparatus suitable for use in the method of the invention.

Abstract: Apparatuses and methods of optically analyzing fluid within a pipette are described herein. In an embodiment, an optical reader subassembly includes a pipette configured to aspirate and hold a fluid sample within its tip, a housing configured to receive at least the tip of the pipette through a reentrant seal so that the tip of the pipette is located in a light tight manner within an internal area, a light source positioned to be in proximity to the tip of the pipette when the tip of the pipette is received by the housing, the light source configured to project light through the tip of the pipette and onto the fluid sample held within the tip, and an optical sensor configured to take a reading of the fluid sample held within the tip of the pipette without any of the fluid sample being injected from the pipette.

Abstract: Described are the discovery, synthesis and pharmacological characterization of ?-opioid receptor-selective positive allosteric modulators (? PAMs). These ? PAMs may increase the affinity and/or efficacy of the orthosteric agonists leu-enkephalin and SNC80, as measured by ?-arrestin recruitment and adenylyl cyclase inhibition. The compounds may be useful pharmacological tools to probe the molecular pharmacology of the ? receptor and to explore the therapeutic potential of ? PAMs in diseases such as chronic pain and depression.

Abstract: Detector systems are described, based on a primary binding compound and a secondary binding compound used in combination with a support to detect a target in a sample. The detection systems include a liquid medium hosting a first binding compound specific to a target, the first binding compound comprising a label; and a solid medium hosting a second binding compound specific to the target, the second binding compound being different from and non-competitive with respect to the first binding compound.

Abstract: Provided herein are multiplex assays for detecting antibodies indicative of presence and stage of syphilis infection in an individual. Individuals infected with syphilis produce antibodies directed to syphilis components and the lipid cellular debris associated with the infection. The present disclosure represents the first combination of these diverse antibody targets in a single assay.

Abstract: The invention relates to methods, kits and compositions using CD247 as a biomarker for assessing the efficacy and selecting an appropriate therapy such as chemotherapeutic, biological therapy or combined therapy for treating a subject suffering from a pathologic disorder that leads to a chronic-inflammatory condition.

Abstract: The invention relates to immunomodulation of cells and the detection and use thereof, for example, in drug screening, including methods, compositions and systems therefor, or in an aspect of healthcare, such as prognosis, diagnosis, an aspect of treatment, monitoring, and the like, and methods, compositions, and systems thereof.

Abstract: The invention relates to immunomodulation of cells and the detection and use thereof, for example, in drug screening, including methods, compositions and systems therefor, or in an aspect of healthcare, such as prognosis, diagnosis, an aspect of treatment, monitoring, and the like, and methods, compositions, and systems therefor.

Abstract: The present invention relates to a method for the prognosis of bone metastasis in triple negative (including basal-like) breast cancer or, alternatively, ER+ breast cancer (including luminal A and B) which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level, amplification or translocation. The invention also relates to a method for predicting early bone metastasis in a subject suffering breast cancer. The invention also relates to a c-MAF inhibitor as therapeutic agent for use in the treatment of triple negative (including basal-like) breast cancer metastasis or, alternatively, ER+ breast cancer (including luminal A and B) metastasis. The invention relates to kits for predicting bone metastasis and predicting the clinical outcome of a subject suffering from bone metastasis.

Abstract: The biological information measurement system of the present invention includes a test subject-side device provided in a toilet installation room, and a server communicable with the test subject-side device, the test subject-side device includes a sulfur-containing gas sensor sensitive to sulfur-containing gas and outputting detection data, a transmitter-receiver transmitting measurement data including detection data of the sulfur-containing gas detected by the sulfur-containing gas sensor to the server, and the server includes a database in which measurement data including detection data of sulfur-containing gas detected by the sulfur-containing gas sensor is accumulated and recorded with dates and times of defecation acts by being associated with test subject identification information, and server-side data analyzer that analyzes physical condition of a test subject on the basis of a time-dependent variation tendency of the measurement data accumulated and recorded in the database.

Abstract: Disclosed herein are panels related to the diagnosis or recognition of colon and colorectal cancer in a subject. The disclosed panels and related methods are used to predict or assess colon tumor status in a patient. They can be used to determine nature of tumor, recurrence, or patient response to treatments. Some embodiments of the methods include generating a report for clinical management.

Abstract: Aspects of the disclosure relate to improved methods for predicting whether a prostate tissue biopsy obtained from a subject will contain detectable prostate cancer. In some embodiments, the disclosure provides improved prostate antigen standards for quantifying levels of prostate antigens.

Abstract: In one aspect, methods of sensing are described herein. In some embodiments, such a method comprises disposing a population of luminescent species in a test sample, exposing the test sample to electromagnetic radiation having a wavelength corresponding to an excitation wavelength of the luminescent species, detecting light emitted by the luminescent species within a detection region of the test sample, and correlating the light emitted by the luminescent species within the detection region to a presence or absence of an analyte within the test sample. The luminescent species, in a non-aggregated state, exhibits luminescence blinking and, in an aggregated state, does not exhibit luminescence blinking. Additionally, correlating the light emitted by the luminescent species to the presence or absence of the analyte comprises determining whether the light emitted by the luminescent species within the detection region is blinking luminescence or non-blinking luminescence.

Abstract: The present invention is in the field of clinical diagnostics. Particularly the present invention relates to the prognosis of adverse events in patients with stable chronic heart failure or being suspected of having stable chronic heart failure by determination of the level of Procalcitonin (PCT).

Abstract: One aspect as reported herein is a method for detecting a rat antibody in a serum or plasma sample (obtained) from a mouse comprising the steps of a) providing the sample to be analyzed, b) incubating said serum or plasma sample with an antibody that specifically binds to rat IgG and that does not specifically bind to mouse IgG, wherein the antibody is i) a mixture of an antibody binding to rat kappa light chain and an antibody binding to rat lambda light chain, or ii) a mixture of an antibody binding to rat IgG1 with an avidity of 4.1×1010 M?1 or more, an antibody binding to rat IgG2a with an avidity of 8.6×109 M?1 or more, an antibody binding to rat IgG2b with an avidity of 6.4×1010 M?1or more and an antibody binding to rat IgG2c with an avidity of 9.

Abstract: The invention relates to a method for determining a biomarker on single cell level by counting a first portion of a cell sample, subjecting said first portion to conditions whereby the biomarker is fragmented, adding to a known number n(k) of labelled biomarker fragments, measuring a first and a second parameter of said first portion, wherein said first parameter corresponds to the amount of said biomarker fragment and said second parameter corresponds to the amount of said labelled biomarker fragment yielding a biomarker fragment value, v(u), and a labelled biomarker fragment value v(k), respectively, and relating v(u) and v(k) with n(k) and c(1), thereby determining an average number of biomarker molecules per cell, m(u), of said first portion.

Abstract: The present invention relates to the field of biomarkers. More specifically, the present invention relates to biomarkers useful in diagnosing brain injury or neurodegeneration. In one embodiment, a method for diagnosing brain injury in a patient comprises the steps of (a) obtaining a sample from the patient; (b) determining the ratio of citrullinated to unmodified arginine residues at one or more arginine residues of one or more brain injury biomarker proteins; and (c) correlating the ratio to a patient having brain injury or to a patient not having brain injury, thereby providing the diagnosis.

Abstract: The present invention relates to methods and compositions for specifically and quantitatively detecting galectin-3 in a sample. Embodiments of the invention include a detection assay in which a capture binding moiety and a labeled binding moiety specifically recognize non-overlapping epitopes on the N-terminus of galectin-3. Further embodiments are directed to a method for establishing ranges of galectin-3 concentrations indicative of the presence and severity of heart failure in a subject and a method for predicting the clinical outcome of a subject based upon galectin-3 concentration.

Abstract: The present invention provides biomarkers of oxidative stress in subjects with retinitis pigmentosa, age-related macular degeneration, diabetic retinopathy, Fuchs' dystrophy, diabetic macular edema (DME), geographic atrophy, Stargardt's disease, or retinal vein occlusion (RVO), and their use in identifying subjects in need of treatment and methods for staging the severity of the disease.

Abstract: The invention concerns the identification of specific polypeptides, fragments variants thereof which can be used as markers for the efficacy of immunotherapy, particular for predicting responsiveness of a patient to immunotherapy.

Abstract: Methods and devices for diagnosing, monitoring, or determining diabetic nephropathy or an associated disorder in a mammal are described. In particular, methods and devices for diagnosing, monitoring, or determining diabetic nephropathy or an associated disorder using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described.